Evidence map›Paper›PMID 26826310›Full record

ArticleExperimental hematology2016

Treating leukemia at the risk of inducing severe anemia.

Wendy S Chen, Helen He Zhu, Gen-Sheng Feng

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Chest CT Findings and Differential Diagnosis ofJournal of healthcare engineering · 2021
    Article
  2. Biomedical optics express · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Wendy S ChenDivision of Biological Sciences and Department of Pathology, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA.
Helen He ZhuState Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gen-Sheng FengDivision of Biological Sciences and Department of Pathology, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA. Electronic address: gfeng@ucsd.edu.
University of California, San Diego · USShanghai Jiao Tong University · CN

Funding

Dissection of Pten-regulated signals in hepatopathogenesisR01CA188506 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2015 to 2019
$1.9M
Molecular and Cellular Communications in Liver TumorigenesisR01CA176012 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2014 to 2019
$1.7M
Shp2 and Pten in Leukemia and AnemiaR01HL129763 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2015 to 2018
$1.6M
NCI NIH HHS R01 CA176012NCI NIH HHS R01CA176012NCI NIH HHS R01 CA188506NCI NIH HHS R01CA188506NHLBI NIH HHS R01 HL129763NHLBI NIH HHS R01HL129763
6 · The paper itself

Abstract

Anemia is a frequently observed adverse effect in cancer patients who receive chemotherapy or drugs designed to block specific oncogenic signaling pathways, although the underlying mechanisms are poorly understood. An article first published online (Zhu HH, Luo X, Zhang K, et al. Proc Natl Acad Sci USA 2015;112:13342-13347) presented data indicating that cell type-specific pathway cross-talk is likely an important mechanism to consider. Shp2 and Pten, two master regulators of central cytoplasmic signaling pathways, oppose each other in myeloproliferation and leukemogenesis, but cooperate in promoting erythropoiesis. Thus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.

Indexed as

AnemiaAnimalsEnzyme InhibitorsErythropoiesisLeukemiaMiceMice, KnockoutModels, GeneticMutationProtein Tyrosine Phosphatase, Non-Receptor Type 11PTEN PhosphohydrolasePyridonesPyrimidinonesRisk FactorsSignal TransductionEnzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11PTEN PhosphohydrolasePten protein, mousePtpn11 protein, mousePyridonesPyrimidinonestrametinib

Identifiers

PMID26826310
PMCPMC5331859
OpenAlexW2285533383

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.